What is Think Bioscience?
Think Bioscience operates at the intersection of synthetic biology and protein biophysics, positioning itself as a leader in the next generation of pharmaceutical innovation. By leveraging advanced computational chemistry and applied enzymology, the company identifies and develops first-in-class therapeutics for diseases characterized by high unmet medical needs. Their market position is defined by a focus on targets that have previously eluded traditional drug discovery methods, effectively expanding the druggable proteome through a multidisciplinary scientific framework.
How much funding has Think Bioscience raised?
Think Bioscience has raised a total of $73.9M across 3 funding rounds:
Angel/Pre-Seed
$1.9M
Seed
$17M
Series A
$55M
Angel/Pre-Seed (2021): $1.9M, investors not publicly disclosed
Seed (2022): $17M led by Innovation Endeavors, AV8 Ventures, and Xora Innovation
Series A (2026): $55M supported by Janus Henderson Investors, Regeneron Ventures, MBX Capital, Colorado Venture Partners, AV8 Ventures, Innovation Endeavors, and Crescent Enterprises
Key Investors in Think Bioscience
Janus Henderson Investors
Janus Henderson is a global investment management firm that provides a broad range of investment solutions and advisory services to institutional investors, financial professionals, and individual clients.
Regeneron Ventures
Regeneron Ventures is a company focused on investing in innovative biotechnology and pharmaceutical companies to support the development of groundbreaking therapies.
MBX Capital
MBX Capital is a boutique venture capital firm that partners with and creates healthcare and biotechnology companies that are disrupting conventions in service to public health.
What's next for Think Bioscience?
With the successful closure of this Series A financing, Think Bioscience is poised to transition from a research-intensive startup into a clinical-stage organization. The capital will be deployed to scale its internal pipeline and enhance its computational discovery engine. Strategic priorities include the advancement of lead candidates into preclinical development and the expansion of its collaborative network with global life sciences partners. As the company matures, it remains focused on validating its platform's efficacy in addressing complex biological pathways, setting the stage for potential future partnerships or long-term commercialization efforts in the biotechnology sector.
See full Think Bioscience company page
